Diagnosis and Treatment of Cutaneous Lupus Erythematosus

Conclusions

• Cutaneous lupus erythematosus is a heterogeneous autoimmune disease with major skin morbidity and substantial impact on quality of life, especially when lesions are disfiguring or scar.
• Accurate diagnosis depends on clinical assessment supported by histopathology and selected laboratory testing, with careful distinction between CLE subtypes and non-specific manifestations.
• Patients diagnosed with cutaneous lupus should be screened for systemic involvement and then monitored regularly, because a minority will progress to systemic lupus over time.
• The risk of progression to systemic lupus varies by subtype, with acute cutaneous lupus carrying the highest association and chronic localized forms generally carrying lower risk.
• There is still no approved therapy specifically for cutaneous lupus erythematosus, so current management relies on prevention, topical treatment, and off-label systemic agents.
• Photoprotection, smoking cessation, medication review, and vitamin D support are key preventive measures that should accompany all treatment plans.
• Hydroxychloroquine remains the cornerstone first-line systemic treatment, and checking drug levels may help identify nonadherence before escalating therapy.
• Systemic corticosteroids can be useful for severe flares but should be used briefly and tapered off as soon as possible because long-term exposure is not recommended.
• Refractory disease may respond to agents such as methotrexate, mycophenolate mofetil, dapsone, retinoids, thalidomide, or lenalidomide, but these options are limited by side effects and off-label use.
• Novel biologic and targeted therapies, particularly anifrolumab and other interferon- or plasmacytoid dendritic cell–directed drugs, appear promising for CLE and may fill an important unmet need.
• Early studies suggest topical JAK inhibition and other pathway-targeted approaches may improve CLE, but more robust trials are needed before these treatments can be routinely adopted.
• Updated, CLE-specific guidelines are needed not only to standardize care but also to support reimbursement decisions and improve access to newer therapies.
• Optimal care for cutaneous lupus requires collaboration between dermatology and rheumatology, combining experience, monitoring, and shared decision-making for better patient outcomes.